A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
NCT ID: NCT02320773
Last Updated: 2024-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
863 participants
OBSERVATIONAL
2014-11-25
2016-07-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)
NCT02386072
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
NCT02216214
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00688688
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00912964
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
NCT00662909
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1. OAB patients taking Betmiga®
OAB patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment
Betmiga®
Oral
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Betmiga®
Oral
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients whose physician has made the decision to prescribe Betmiga® as part of routine clinical practice and who are about to start treatment.
Exclusion Criteria
* Contraindication(s) as per the Betmiga® Summary of Product Characteristics (SPC).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Europe Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Affairs Europe
Role: STUDY_DIRECTOR
Astellas Pharma Europe Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site CZ42009 UROMEDA s. r. o.
Brno, , Czechia
Site CZ42003 Fakultni nemocnice Brno-Bohunice
Brno, , Czechia
Site CZ42006 Hospital Kyjov
Kyjov, , Czechia
Site CZ42002 Fakultni nemocnice Kralovske Vinohrady
Prague, , Czechia
Site CZ42007 MEDICON a.s.
Prague, , Czechia
Site CZ42008 Oblastni nemocnice Pribram
Příbram, , Czechia
Site CZ42004 Krajská nemocnice Tomáše Bati
Zlín, , Czechia
Site DK45003 Sygehus Vendsyssel, Frederikshavn
Frederikshavn, , Denmark
Site DK45004 Regionshospitalet Herning
Herning, , Denmark
Site GR30002 University Hospital of Crete
Heraklion, Crete, Greece
Site GR30009 PGH Laiko
Athens, , Greece
Site GR30001 General Hospital of Athens "Alexandra"
Athens, , Greece
Site GR30007 Sismanoglio General Hospital
Athens, , Greece
Site GR30011 General Hospital of Heraklion 'Venizelio-Pananio'
Heraklion, , Greece
Site GR30008 University Hospital of Ioannina
Ioannina, , Greece
Site GR30013 University Hospital of Ioannina
Ioannina, , Greece
Site GR30005 University Hospital of Larissa
Larissa, , Greece
Site GR30003 University Hospital of Patras
Pátrai, , Greece
Site GR30006 Papageorgiou General Hospital
Thessaloniki, , Greece
Site GR30012 Papageorgiou General Hospital of Thessaloniki
Thessaloniki, , Greece
Site IE35304 Midland Regional Hospital
Mullingar, Co. Westmeath, Ireland
Site IE35302 Coombe Hospital
Dublin, , Ireland
Site IE35303 Kerry General Hospital
Kerry, , Ireland
Site SK42101 Univerzitná nemocnica Bratislava - Kramáre
Bratislava, , Slovakia
Site SK42106 UROCENTRUM LEVICE, s.r.o.
Levice, , Slovakia
Site SK42102 UROAMB, s.r.o.
Liptovský Mikuláš, , Slovakia
Site SK42104 Urologicka ambulancia, Miramed, sro
Rimavská Sobota, , Slovakia
Site SK42107 Private Urological Care Center
Trenčín, , Slovakia
Site SK42103 CMFF, sro
Vranov nad Topľou, , Slovakia
Site SK42105 ProCare Ziar nad Hronom
Žiar nad Hronom, , Slovakia
Site ES34005 Corporació Sanitaria Parc Taulí
Sabadell, Barcelona, Spain
Site ES34012 H. de Mendaro
Mendaro, Guipuzcoa, Spain
Site ES34015 Centro Médico Teknon
Barcelona, , Spain
Site ES34007 Hospital Universitario Vall D'Hebron
Barcelona, , Spain
Site ES34017 Hospital de Mollet
Barcelona, , Spain
Site ES34020 Hospital Universitario Basurto
Bilbao, , Spain
Site ES34009 Hospital Comarcal Santiago Apostol
Burgos, , Spain
Site ES34021 H. de Donostia
Donostia / San Sebastian, , Spain
Site ES34019 Hospital Universitario Lucus Augusti
Lugo, , Spain
Site ES34011 Hospital del Rio Hortega
Valladolid, , Spain
Site ES34010 Policlínico de Vigo, S.A.-POVISA
Vigo, , Spain
Site SE46002 Urologkliniken Carlanderska
Gothenburg, , Sweden
Site GB44005 Bradford Royal Infirmary
Bradford, , United Kingdom
Site GB44011 Royal Blackburn Hospital
Burnley, , United Kingdom
Site GB44016 Addenbrookes Hospital
Cambridge, , United Kingdom
Site GB44009 St. Richards Hospital
Chichester, , United Kingdom
Site GB44007 Northampton General Hospital
Cliftonville, , United Kingdom
Site GB44015 University Hospital Coventry
Coventry, , United Kingdom
Site GB44008 Croydon University Hospital
Croydon, , United Kingdom
Site GB44003 Derriford Hospital
Derriford, , United Kingdom
Site GB44019 Northern Devon Healthcare
Devon, , United Kingdom
Site GB44001 Medway Hospital
Gillingham, , United Kingdom
Site GB44004 Southern General Hospital
Glasgow, , United Kingdom
Site GB44013 Hinchingbrooke Hospital
Huntingdon, , United Kingdom
Site GB44010 The Freeman Hospital
Newcastle upon Tyne, , United Kingdom
Site GB44014 The Queen Elizabeth Hospital King's Lynn NHS Trust
Norfolk, , United Kingdom
Site GB44002 The Royal Berkshire Hospital
Reading, , United Kingdom
Site GB44018 Salisbury District Hospital
Salisbury, , United Kingdom
Site GB44017 Sunderland Royal University Hospital
Sunderland, , United Kingdom
Site GB44006 New Cross Hospital
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Freeman R, Foley S, Rosa Arias J, Vicente E, Grill R, Kachlirova Z, Stari A, Huang M, Choudhury N. Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study. Curr Med Res Opin. 2018 May;34(5):785-793. doi: 10.1080/03007995.2017.1419170. Epub 2018 Jan 10.
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on the Astellas Clinical Study Results website.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
178-MA-1002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.